Abstract In this study, a precise and reliable ultra-high performance liquid chromatography (UHPLC) method for the simultaneous determination of non-canonical (norvaline and norleucine) and standard amino acids (aspartic acid, glutamic acid, serine, histidine, glycine, threonine, arginine, tyrosine, methionine, valine, phenylalanine, isoleucine, leucine) in biopharmaceutical-related fermentation processes was established. After pre-column derivatization with ortho-phthaldialdehyde and 2-mercaptoethanol, the derivatives were separated on a sub-2 lm particle C 18 reverse-phase column. Identification and quantification of amino acids were carried out by fluorescence detection. To test method feasibility on standard HPLC instruments, the assay was properly transferred to a core-shell particle C 18 reverse-phase column. The limits of detection showed excellent sensitivity by values from 0.06 to 0.17 pmol per injection and limits of quantification between 0.19 and 0.89 pmol. In the present study, the newly established UHPLC method was applied to a recombinant antibody Escherichia coli fermentation process for the analysis of total free amino acids. We were able to specifically detect and quantify the unfavorable amino acids in such complex samples. Since we observed trace amounts of norvaline and norleucine during all fermentation phases, an obligatory process monitoring should be considered to improve quality of recombinant protein drugs in future.
Introduction
Apart from the 20 standard amino acids, several noncanonical amino acids can be found in organisms. The amino acids norvaline and norleucine belong to a group of natural branched amino acid analogs synthesized by the biotechnological relevant bacterium Escherichia coli (E. coli) and other gram-negative species (Kisumi et al. 1976; Sugiura et al. 1981) . Initially norvaline was described as a natural component of an antifungal peptide produced in Bacillus subtilis (Nandi and Sen 1953) , while norleucine was found to be formed in leucine regulatory mutant variants of Serratia marcescens (Kisumi et al. 1976) .
The biosynthesis of norleucine and norvaline by E. coli as byproducts of the branched chain amino acid biosynthesis occurs via the promiscuous enzymes of the (iso)-leucine pathway (Bogosian et al. 1989; Sycheva et al. 2007; Soini et al. 2008 ). Due to their broad range of keto acid substrate acceptance, the leuABCD-operon enzymes are proposed to facilitate a direct carbon chain elongation from the central intermediate pyruvate to the branched chain amino acid precursor 2-ketobutyrate which is synthesized from threonine under standard conditions. The following extension reactions of 2-ketobutyrate are catalyzed by the leucine biosynthesis enzymes isopropylmalate synthase (IPMS, leuA gene), isopropylmalate isomerase (IPMI, leuCD genes) and isopropylmalate dehydrogenase (IPMD, leuB gene). Enzymatic specificity of IPMS has not been investigated in E. coli yet but is known for a variety of substrates of the highly conserved homolog protein in Salmonella typhimurium (Kohlhaw et al. 1969 ) which can utilize, e.g., 2-ketobutyrate and pyruvate, for condensation with acetyl-CoA. Subsequent conversion of the intermediate compounds by IPMI and IPMD via this keto acid elongation pathway forms 2-ketovalerate and 2-ketocaproate. The last step in norleucine and norvaline biosynthesis consists of the transamination of 2-ketocaproate and 2-ketovalerate by aminotransferases IlvE, TyrA and AvtA.
The specific physiological conditions leading to formation of these modified amino acids in E. coli are not fully understood but experimental data suggest a strong connection to glucose overflow metabolism and pyruvate accumulation in fermentation processes (Soini et al. 2008 ). An additional proof for this hypothesis might be seen in the presence of norleucine and norvaline accumulation in E. coli knock-out mutants of the ilvA gene, which is responsible for 2-ketobutyrate synthesis from threonine (Sycheva et al. 2007) .
Recently non-canonical amino acids have gained substantial interest when found incorporated into proteinbased biopharmaceuticals produced by recombinant E. coli fermentation processes. Some examples of these unwanted misincorporations are the findings of norleucine in recombinant interleukin 2 Tsai et al. 1988) and human brain derived factor (Sunasara et al. 1999) or norvaline in recombinant hemoglobin (Apostol et al. 1997) . The incorporation of norleucine and norvaline occurs via misaminoacylation of the cognate tRNA during translation. Norleucine is known to be an isostructural analog of methionine, while norvaline is known to be an analog of leucine (Budisa et al. 1995) . They can be mischarged to tRNA met and tRNA leu by aminoacyl-tRNA synthetases resulting in substitutions within the synthesized protein Apostol et al. 1997; Reynolds et al. 2010) . To insure the final quality of recombinant drugs, every modification of the active protein drug needs intensive analytical characterization according to the standards of regulatory authorities such as the US Food and Drug Administration and European Medicines Agency (Berkowitz et al. 2012; Ahmed et al. 2012) . For this reason, early detection of non-canonical amino acids during process development in biopharmaceutical industry is required.
There is no universal technique for the detection and quantification of the mentioned amino acids in biological samples. The most common approaches for amino acid analysis include: liquid chromatography separation coupled with optical detection (Le Boucher et al. 1997; Joseph and Davies 1983; Fekkes 1996; Molnár-Perl 2005; PappaLouisi et al. 2007; Ilisz et al. 2012 ) and mass spectrometrybased detection methods coupled to prior separation by liquid or gas chromatography (Husek et al. 2008; Waterval et al. 2009; Armenta et al. 2010; Dettmer et al. 2012 ). However, these methods suffer from the limited number of covered amino acids, lack of separation due to slow mass transfer kinetics, ion suppression or expensive equipment (Kaspar et al. 2009 ).
In recent years, the ultra-high performance liquid chromatography (UHPLC) builds a new class of liquid chromatography with increased separation, sensitivity and speed (Wu and Clausen 2007; Fekete et al. 2012 ) of amino acid analysis. Either by the application of sub-2 lm material or core-shell particles, this approach achieves higher plate counts and column efficiency in comparison to conventional column materials (Guiochon and Gritti 2011; Gritti and Guiochon 2012) .
In this study, a precise UHPLC method using a sub-2 lm C 18 particle column was established for the simultaneous analysis of the non-canonical amino acids norleucine, norvaline and their corresponding isostructural compounds. Further method development implementing core-shell particle C 18 material was carried out in order to allow the ultra-high performance assay on standard HPLC instrumentation. Both methods were also evaluated for crucial validation parameters. Capitalizing on the advantages of the core-shell method, application in recombinant antibody production was proved to be feasible. To our knowledge, this is the first report on OPA derivatization based simultaneous analysis of norleucine and norvaline by state of the art core-shell technique.
Materials and methods

Chemicals
Norleucine, norvaline, and Fluka A2161 amino acid reference solution for fluorescence detection, OPA and 2-mercaptoethanol were purchased from Sigma-Aldrich (Taufkirchen, Germany).
Hydrochloric acid, sodium hydroxide, di-sodium hydrogen phosphate, sodium dihydrogen phosphate dihydrate, methanol and tetrahydrofuran were from Merck (Darmstadt, Germany). Acetonitrile was purchased from VWR (Darmstadt, Germany). All chemicals were at highest available analysis grade. Water was purified by Milli-Q water purification system (Millipore, Bredford, USA).
Instrumentation
A JASCO X-LC HPLC system (JASCO Corporation, Japan), containing two pumps, autosampler, intelligent column thermostat and fluorescence detector was used. For instrument control, data acquisition and analysis, JASCO Chrompass software was employed. Chromatographic separations were realized with Nucleodur C18 Gravity column (150 9 2.0 mm, 1.8 lm particle size), MachereyNagel, Düren, Germany) with column inlet filter Rheodyne (0.5 lm pore size, 3.0 mm I.D., Macherey-Nagel, Düren, Germany) and Sunshell C18 column (150 9 2.0 I.D. mm, 2.6 lm, dichrom, Marl, Germany).
Chromatographic separation and quantification
In a reaction vial with conical insert, 30 lL OPA was added to 30 lL sample and mixed by autosampler unit. After 30 s reaction time, 1 lL of the solution was injected onto column. Mobile phase A was aqueous buffer (25 mM Na 2 HPO 4 /NaH 2 PO 4 , pH 7. Fermentation conditions and preparation of recombinant E. coli samples Fermentation samples were obtained from cultivations of E. coli RV308 carrying plasmid p41-B10aP for VHH antibody fragment as described earlier (Horn et al. 1996; Habicht et al. 2007 ). Fermentation samples were prepared by quenching of fermentation broth containing medium and cells with -40°C cold 60 % methanol and subsequent shock frozen in liquid nitrogen. Until analysis samples were stored at -80°C. For amino acid analysis, samples were diluted to same biomass concentration with 0.9 % NaCl, followed by sonification for 10 min on ice. Removal of cell debris and deproteinization were carried out by centrifugation for 10 min (4°C, 16,0009g) and ultrafiltration of supernatant using Amicon Ultra 3 kDa cut-off filter membranes.
Results and discussion
Chromatographic separation and fluorescence detection of norleucine, norvaline and standard amino acids Based on the known advantages in sensitivity, selectivity and simplicity, the OPA derivatization (Roth 1971; Molnár-Perl 2005; Kaspar et al. 2009 ) was used for fully automated pre-column derivatization of reference amino acid solutions. We initially tested the reversed-phase HPLC method described by Kroemer (2005) as it reported good separation of the canonical branched chain amino acids leucine, valine, isoleucine. Although either norleucine or norvaline is separately used as traditional internal standards in analyses, this method failed in the simultaneous separation of norvaline, norleucine and their corresponding closely eluting amino acids valine and leucine. The obtained chromatograms showed no peak separation of these highly hydrophobic and isostructural amino acids (data not shown).
As a consequence, we chose a sub-2 lm C 18 particle column (Nucleodur C18 Gravity) together with a smaller inner diameter of 2.1 mm to further increase separation efficiency of the method. To circumvent the compromising effect of a decreased column diameter, the number of theoretical plates was increased by keeping the column length at a dimension of 150 mm. The existing gradient protocol was optimized for UHPLC and applied to a reference solution.
All obtained reference chromatograms showed clear baseline resolution and symmetric peak shape for the noncanonical amino acids norvaline, norleucine and their proteinogenic isostructural relatives valine, leucine, isoleucine and methionine (data not shown). Following on from that, we were aiming to overcome the limitation of sub-2 lm particles to special equipment caused by high column back pressure (Fekete et al. 2012; Song et al. 2012a, b) of about 700 bar in our case respectively. Therefore, we directly transferred chromatographic conditions to the application of a 2.6-lm core-shell C 18 column (Sunshell C18) with the same dimensions (150 mm 9 2.1 mm). The obtained separation data were comparable to those from the sub-2 lm particle column (Fig. 1) showing equal resolution properties.
Emphasizing the enhanced performance of the hereby newly established method, the indirect resolution of amino acid derivatives that differ in hydrophobicity by only one methyl group (e.g., methionine/norleucine) was facilitated. Furthermore, the results show resolution of isostructural amino acids in both tested column materials.
Analytical method validation
To evaluate the method, we determined the following validation parameters: linearity range, limits of detection (LOD), limits of quantification (LOQ), repeatability of retention time and intra-day precision (Table 1 ). The detection of OPA derivatives at 455 nm indicated linearity in the performed calibration range of 2.5-12.5 pmol (per 1 lL injection volume) with correlation coefficients of [0.99 for each analyte. LOD and LOQ were calculated as signal-to-noise ratios of 3 and 10, respectively. The resulting sensitivities (Table 1) were stated as pmol per injection, hence related to the actual on-column amounts of OPA derivatives.
The LOD for all OPA amino acids ranged from from 0.06 to 0.17 pmol per injection, LOQ were between 0.19 and 0.89 pmol. Comparing the new method to current OPA related studies (Pereira et al. 2008; Kaspar et al. 2009; Arrieta and Prats-Moya 2012) including analysis of complex biological matrices, it was possible to achieve a significant increase in sensitivity of chromatographic results. Overall sensitivity parameters of the method were also comparable to recent reports on sub-2 lm particle column (Mayer et al. 2010 ) and core-shell (Song et al. 2012a, b) amino acid analysis using different derivatization procedures and detection options. The obtained data show an overall improvement of detection sensitivity from lM to the nM range, which is a magnitude lower then LOD's for OPA derivative analysis reported earlier (Wan et al. 2000) .
Simultaneous analysis of non-canonical amino acids in recombinant antibody fermentation To investigate practical utility for the determination of nonproteinogenic amino acids in biopharmaceutical relevant processes, the method was applied to recombinant antibody fermentation samples of E. coli at different time points. The chromatograms shown in Fig. 2 were obtained from E. coli fermentations producing the recombinant camelid antibody domain B10 (Habicht et al. 2007) .
Trace levels of norleucine and norvaline with concentrations of 0.66 and 0.92 lM were detected (Table 2) in early phase of the fermentation (batch phase). The values for both amino acids increased during glucose-limited growth up to 4.47 lM (Nleu) and 9.42 lM (Nval). Upon induction of the recombinant model antibody for 6 h, a significant decrease of norvaline and norleucine to a concentration of 2.60 and 0.44 lM was observed. This supports the argument of incorporation of these amino acids into recombinant proteins after induction (Sunasara et al. 1999; Apostol et al. 1997) . The corresponding free pools of leucine and valine increased from the point of antibody production which might be due to the amino acid depletion caused by recombinant protein production (Bogosian et al. 1989) .
The data shed new light into the occurrence of noncanonical amino acids since this is the first report on physiological free Nval or Nleu during balanced growth of E. coli. Biosynthesis of these compounds was proposed to be restricted to induction of recombinant gene expression (Apostol et al. 1997) or metabolic imbalance (Soini et al. 2008 ). Since our new method provides a significantly improved sensitivity, it seems to be plausible. A possible reason for this finding could be the higher sensitivity of the new method. The results further indicate that this method can be applied for the simultaneous monitoring of low level concentrations of norleucine and norvaline in complex biological samples.
Conclusion
The present novel approach allows the simultaneous, sensitive and precise detection and quantification of the noncanonical amino acids norleucine and norvaline. In addition, their canonical isostructural compounds leucine, Analysis of the non-canonical and standard amino acids by UHPLC 1229 isoleucine, valine, methionine and eight other proteinogenic amino acids can be efficiently resolved and quantified. By the analysis of recombinant E. coli antibody fermentation, the method was proved to be applicable to complex biological samples. No expensive instrumentation or time-consuming derivatization procedures are needed for assay performance. Taken together, this method provides a powerful tool in biopharmaceutical process analysis and further an improvement of protein based drug development.
